Aberrant expression of miRNA cluster in 14q32 region is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F68407700%3A21230%2F15%3A00227293" target="_blank" >RIV/68407700:21230/15:00227293 - isvavai.cz</a>

Výsledek na webu

<a href="http://www.sciencedirect.com/science/article/pii/S2210776215000344" target="_blank" >http://www.sciencedirect.com/science/article/pii/S2210776215000344</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cancergen.2015.03.003" target="_blank" >10.1016/j.cancergen.2015.03.003</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Aberrant expression of miRNA cluster in 14q32 region is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment

Popis výsledku v původním jazyce

BACKGROUND: Lenalidomide is a novel thalidomide analog with immunomodulatory and antiangiogenic effects that has been successfully used for the treatment of low- and intermediate-1 risk myelodysplastic syndromes (MDS) with a del(5q) aberration. METHODS:Because information about the influence of lenalidomide on the miRNA transcriptome is limited, we performed miRNA expression profiling of bone marrow CD34+ cells obtained from MDS patients with del(5q) abnormality who had been subjected to lenalidomide treatment. To define differences in miRNA expression, we performed paired data analysis to compare the miRNA profiles of patients before and during lenalidomide treatment and those of healthy donors. RESULTS: The analysis showed that miRNAs clustering tothe 14q32 region had a higher expression level in patient samples before treatment than in the healthy control samples, and this elevated expression was diminished following lenalidomide administration. CONCLUSION: Because some of the 14q

Název v anglickém jazyce

Aberrant expression of miRNA cluster in 14q32 region is associated with del(5q) myelodysplastic syndrome and lenalidomide treatment

Popis výsledku anglicky

BACKGROUND: Lenalidomide is a novel thalidomide analog with immunomodulatory and antiangiogenic effects that has been successfully used for the treatment of low- and intermediate-1 risk myelodysplastic syndromes (MDS) with a del(5q) aberration. METHODS:Because information about the influence of lenalidomide on the miRNA transcriptome is limited, we performed miRNA expression profiling of bone marrow CD34+ cells obtained from MDS patients with del(5q) abnormality who had been subjected to lenalidomide treatment. To define differences in miRNA expression, we performed paired data analysis to compare the miRNA profiles of patients before and during lenalidomide treatment and those of healthy donors. RESULTS: The analysis showed that miRNAs clustering tothe 14q32 region had a higher expression level in patient samples before treatment than in the healthy control samples, and this elevated expression was diminished following lenalidomide administration. CONCLUSION: Because some of the 14q

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

EB - Genetika a molekulární biologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2015

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Cancer Genetics

ISSN

2210-7762

e-ISSN

—

Svazek periodika

208

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

NL - Nizozemsko

Počet stran výsledku

6

Strana od-do

156-161

Kód UT WoS článku

000354911400009

EID výsledku v databázi Scopus

2-s2.0-84929294768